Literature DB >> 28578852

Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery.

Slimane Zerdoud1, Anne-Laure Giraudet2, Sophie Leboulleux3, Laurence Leenhardt4, Stéphane Bardet5, Jérôme Clerc6, Marie-Elisabeth Toubert7, Abir Al Ghuzlan8, Pierre-Jean Lamy9, Claire Bournaud10, Isabelle Keller11, Frédéric Sebag12, Renaud Garrel13, Eric Mirallié14, Lionel Groussin15, Elif Hindié16, David Taïeb17.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28578852     DOI： 10.1016/j.ando.2017.04.023

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN： 0003-4266            Impact factor:   2.478


× No keyword cloud information.
  7 in total

1.  [Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

Authors:  Amir Kurtaran; Brigitta Schmoll-Hauer; Christina Tugendsam
Journal:  Wien Med Wochenschr       Date:  2019-12-03

2.  Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.

Authors:  Nathalie Chereau; Etienne Dauzier; Gaëlle Godiris-Petit; Séverine Noullet; Isabelle Brocheriou; Laurence Leenhardt; Camille Buffet; Fabrice Menegaux
Journal:  Langenbecks Arch Surg       Date:  2018-02-14       Impact factor: 3.445

Review 3.  Prognostic and predictive value of nuclear imaging in endocrine oncology.

Authors:  Giorgio Treglia; Bernard Goichot; Luca Giovanella; Elif Hindié; Abhishek Jha; Karel Pacak; David Taïeb; Thomas Walter; Alessio Imperiale
Journal:  Endocrine       Date:  2019-11-16       Impact factor: 3.633

4.  Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system.

Authors:  N Chereau; T O Oyekunle; A Zambeli-Ljepović; H S Kazaure; S A Roman; F Menegaux; J A Sosa
Journal:  Br J Surg       Date:  2019-04-23       Impact factor: 6.939

5.  Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC).

Authors:  Nadia Bouzehouane; Pascal Roy; Myriam Decaussin-Petrucci; Mireille Bertholon-Grégoire; Chantal Bully; Agnès Perrin; Helene Lasolle; Jean-Christophe Lifante; Françoise Borson-Chazot; Claire Bournaud
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

6.  Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

Authors:  P W Rosario; G Mourão; M R Calsolari
Journal:  J Endocrinol Invest       Date:  2018-10-23       Impact factor: 4.256

7.  Optimization of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9-12 months after treatment.

Authors:  Fabian Nordell; Ghadir Hallal; Pernilla Asp; Martin Almquist
Journal:  BJS Open       Date:  2021-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.